{"id":1698,"date":"2022-12-14T08:00:00","date_gmt":"2022-12-14T07:00:00","guid":{"rendered":"https:\/\/d36deud6t4mnhi.cloudfront.net\/annualreport\/press-releases\/ipsen-receives-complete-response-letter-for-palovarotene-an-investigational-treatment-for-fibrodysplasia-ossificans-progressiva-2\/"},"modified":"2023-05-20T18:26:18","modified_gmt":"2023-05-20T18:26:18","slug":"ipsen-receives-complete-response-letter-for-palovarotene-an-investigational-treatment-for-fibrodysplasia-ossificans-progressiva-2","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-receives-complete-response-letter-for-palovarotene-an-investigational-treatment-for-fibrodysplasia-ossificans-progressiva-2\/","title":{"rendered":"Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva"},"content":{"rendered":"